Cipla (EU) Limited, UK, a wholly-owned subsidiary of Cipla Limited, has entered into a strategic collaboration with Kemwell Biopharma Private Limited and Manipal Education & Medical Group, marking the inception of a joint venture in the United States. This alliance aims to develop and commercialize novel cell therapy products, addressing major unmet medical needs in […]
Cipla Limited, a leading pharmaceutical company, has announced its decision to further invest approximately INR 42 crore in digital tech company GoApptiv Private Limited. This investment aligns with Cipla’s strategic vision to bolster its presence across the healthcare continuum, particularly in underserved regions, by enhancing access to essential treatments. With the completion of this deal, […]
InvaGen Pharmaceuticals Inc., a wholly-owned subsidiary of Cipla Limited, has announced a voluntary recall of one lot of Vigabatrin for Oral Solution, USP 500mg, to the consumer level in the USA. This recall comes after the discovery of seal integrity issues in the product packaging, which could lead to powder leakage from the pouches. The […]
In a strategic move that amplifies its commitment to the Over-The-Counter (OTC) business, Cipla South Africa, a 100% owned subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA EQ), has signed a binding term sheet to acquire Actor Pharma (Pty) Limited. This acquisition positions Cipla as a leading healthcare player in South Africa, targeting growth opportunities […]
Indian pharma company Cipla Limited has launched a point-of-care testing device called Cippoint in India for infectious diseases, non-communicable diseases, and other health conditions. The device can be used for testing parameters such as cardiac markers, diabetes, infectious diseases, fertility, inflammation, thyroid function, coagulation markers, and metabolic markers. It is CE IVD approved, which means […]
Cipla Ltd said that the US Food and Drug Administration (FDA) has concluded an inspection of the company’s manufacturing facility in Goa and has made six observations. The FDA inspection was carried out from 16-26 August 2022. It is a follow-up to the American regulator’s inspection at the facility in September 2019 and the warning […]
Cipla Limited said that it has acquired a stake of up to 33% in Clean Max Auriga Power LLP, a special purpose vehicle (SPV) focused on production, supply, and distribution of solar and wind or other renewable energy generation. According to the Indian pharma company, the transaction aligns with its commitment to boost the share […]
Cipla Limited said that its fully-owned step-down subsidiary — Cipla Technologies (CipTec) has completed an amendment to a previously signed agreement with US-based Pulmatrix for the development and commercialization of Pulmazole. Pulmatrix is a clinical stage biopharma company focused on developing inhaled therapies for addressing serious pulmonary and non-pulmonary diseases with its iSPERSE technology. As […]
Cipla Limited has reported a profit after tax (PAT) of INR 711 crores for the second quarter of the fiscal year 2022 (Q2 FY22), a 7% increase compared to INR 665 crores for the same quarter of the previous fiscal year. The income from operations of the Indian pharma company for Q2 FY22 was INR […]
Cipla has signed a licensing deal with the Indian subsidiary of US pharma giant Eli Lilly and Company (Lilly) pertaining to the latter’s diabetes treatments — Humalog [Insulin Lispro I.P. (rDNA Origin) injection] and Trulicity (Dulaglutide) in India. In this connection, Lilly will transfer its rights in India to sell, promote, and distribute the two […]